dual integrin alpha-V/beta-1/alpha-V/beta-6 inhibitors (Morphic Therapeutic)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug Namedual integrin alpha-V/beta-1/alpha-V/beta-6 inhibitors (Morphic Therapeutic)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-V/beta-1 inhibitorsIntegrin alpha-V/beta-6 inhibitors
TargetsIntegrin alpha-V/beta-1Integrin alpha-V/beta-6
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMorphic Therapeutic Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMorphic Therapeutic Inc
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A